4/18
10:22 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
4/9
08:09 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $65.00 price target on the stock.
3/8
04:05 pm
gpcr
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
Medium
Report
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
3/8
08:46 am
gpcr
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights [Yahoo! Finance]
Low
Report
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights [Yahoo! Finance]
3/8
08:30 am
gpcr
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
Low
Report
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
3/2
06:06 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.
1/22
05:36 am
gpcr
Here's Why Structure Therapeutics (GPCR) Fell in Q4 [Yahoo! Finance]
Low
Report
Here's Why Structure Therapeutics (GPCR) Fell in Q4 [Yahoo! Finance]